Bradykinin and the pathogenesis of hereditary angioedema.
作者信息
Kaplan Allen P
机构信息
Medical University of South Carolina, Charleston, South Carolina.
出版信息
World Allergy Organ J. 2011 Apr;4(4):73-5. doi: 10.1097/WOX.0b013e318216b7b2.
Abstract
摘要
相似文献
1
Bradykinin and the pathogenesis of hereditary angioedema.缓激肽与遗传性血管性水肿的发病机制
World Allergy Organ J. 2011 Apr;4(4):73-5. doi: 10.1097/WOX.0b013e318216b7b2.
2
HAE Pathophysiology and Underlying Mechanisms.遗传性血管性水肿的病理生理学及潜在机制。
Clin Rev Allergy Immunol. 2016 Oct;51(2):216-29. doi: 10.1007/s12016-016-8561-8.
3
[Bradykinin-induced angioedema: Definition, pathogenesis, clinical presentation, diagnosis and therapy].[缓激肽诱导的血管性水肿：定义、发病机制、临床表现、诊断与治疗]
HNO. 2015 Dec;63(12):885-93; quiz 894-5. doi: 10.1007/s00106-015-0084-8.
4
Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).用缓激肽受体-2拮抗剂（依卡替班）治疗遗传性血管性水肿的急性水肿发作。
J Allergy Clin Immunol. 2007 Jun;119(6):1497-503. doi: 10.1016/j.jaci.2007.02.012. Epub 2007 Apr 5.
5
Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.旁路途径 XII 因子非依赖性激活动脉紧张素转化酶形成级联反应：对遗传性血管性水肿 I 型和 II 型发病机制的影响。
J Allergy Clin Immunol. 2013 Aug;132(2):470-5. doi: 10.1016/j.jaci.2013.03.026. Epub 2013 May 11.
6
The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.依卡替班（一种B2缓激肽受体拮抗剂）在急诊科危及生命的喉血管性水肿中的作用。
Am J Emerg Med. 2015 Mar;33(3):479.e1-3. doi: 10.1016/j.ajem.2014.08.055. Epub 2014 Aug 27.
7
Hereditary angioedema: Looking for bradykinin production and triggers of vascular permeability.遗传性血管性水肿：寻找缓激肽的产生和血管通透性的触发因素。
Clin Exp Allergy. 2019 Nov;49(11):1395-1402. doi: 10.1111/cea.13506. Epub 2019 Oct 21.
8
[Treatment of drugs-associated non-hereditary angioedema mediated by bradykinin].[由缓激肽介导的药物相关性非遗传性血管性水肿的治疗]
Rev Med Suisse. 2016 Jan 13;12(500):11-2.
9
Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.遗传性和获得性C1抑制物依赖性血管性水肿：从病理生理学到治疗
Ann Med. 2016;48(4):256-67. doi: 10.3109/07853890.2016.1162909. Epub 2016 Mar 26.
10
Hereditary angioedema: a disease seldom diagnosed by pediatricians.遗传性血管性水肿：一种儿科医生很少诊断的疾病。
J Pediatr (Rio J). 2021 Mar-Apr;97 Suppl 1(Suppl 1):S10-S16. doi: 10.1016/j.jped.2020.10.011. Epub 2020 Nov 30.
引用本文的文献
1
The prevalence of hereditary angioedema in a Chinese cohort with decreased complement 4 levels.中国补体4水平降低队列中遗传性血管性水肿的患病率。
World Allergy Organ J. 2021 Dec 18;15(1):100620. doi: 10.1016/j.waojou.2021.100620. eCollection 2022 Jan.
2
Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection.荨麻疹和血管性水肿作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即新型冠状病毒肺炎）感染的前驱性皮肤表现。
BMJ Case Rep. 2020 Jul 7;13(7):e236981. doi: 10.1136/bcr-2020-236981.
3
HEREDITARY ANGIOEDEMA DUE TO C1-INHIBITOR DEFICIENCY IN PEDIATRIC PATIENTS IN CROATIA - FIRST NATIONAL STUDY, DIAGNOSTIC AND PROPHYLACTIC CHALLENGES.克罗地亚儿科患者中因C1抑制物缺乏导致的遗传性血管性水肿——首次全国性研究、诊断及预防性挑战
Acta Clin Croat. 2019 Mar;58(1):139-146. doi: 10.20471/acc.2019.58.01.18.
4
THE JEREMIAH METZGER LECTURE NOVEL THERAPEUTIC STRATEGIES OF ALLERGIC AND IMMUNOLOGIC DISORDERS.耶利米·梅茨格讲座：过敏性和免疫性疾病的新型治疗策略
Trans Am Clin Climatol Assoc. 2018;129:250-265.
5
Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.新型、强效和选择性大环血浆激肽释放酶抑制剂的结构导向设计
ACS Med Chem Lett. 2016 Dec 6;8(2):185-190. doi: 10.1021/acsmedchemlett.6b00384. eCollection 2017 Feb 9.
6
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.关于C1抑制剂缺乏的遗传性血管性水肿儿科患者诊断和管理的国际共识。
Allergy. 2017 Feb;72(2):300-313. doi: 10.1111/all.13001. Epub 2016 Sep 8.
7
Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.C1抑制物缺乏所致遗传性血管性水肿患者发作期间的中性粒细胞活化。
Orphanet J Rare Dis. 2015 Dec 10;10:156. doi: 10.1186/s13023-015-0374-y.
8
Complement System Part I - Molecular Mechanisms of Activation and Regulation.补体系统 第一部分——激活与调节的分子机制
Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015.
9
Management of urticaria: not too complicated, not too simple.荨麻疹的管理：既不太复杂，也不太简单。
Clin Exp Allergy. 2015 Apr;45(4):731-43. doi: 10.1111/cea.12465.
10
Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.依卡替班，一种缓激肽受体2抑制剂，用于遗传性血管性水肿发作：前瞻性实验单队列研究。
Sao Paulo Med J. 2014;132(5):261-5. doi: 10.1590/1516-3180.2014.1325652. Epub 2014 Jul 22.
本文引用的文献
1
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.依卡替班，一种新型缓激肽受体拮抗剂，用于遗传性血管性水肿。
N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393.
2
Ecallantide for the treatment of acute attacks in hereditary angioedema.依卡兰肽治疗遗传性血管性水肿急性发作。
N Engl J Med. 2010 Aug 5;363(6):523-31. doi: 10.1056/NEJMoa0905079.
3
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.纳米过滤的 C1 抑制剂浓缩物用于遗传性血管性水肿的治疗。
N Engl J Med. 2010 Aug 5;363(6):513-22. doi: 10.1056/NEJMoa0805538.
4
Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.前激肽释放酶对高分子量激肽原的XII因子非依赖性裂解及C1抑制剂的抑制作用
J Allergy Clin Immunol. 2009 Jul;124(1):143-9. doi: 10.1016/j.jaci.2009.02.006. Epub 2009 Apr 1.
5
Does C-2 kinin exist?C-2激肽存在吗？
J Allergy Clin Immunol. 2005 Apr;115(4):876. doi: 10.1016/j.jaci.2004.12.1132.
6
Interaction of high molecular weight kininogen binding proteins on endothelial cells.高分子量激肽原结合蛋白在内皮细胞上的相互作用。
Thromb Haemost. 2004 Jan;91(1):61-70. doi: 10.1160/TH03-07-0471.
7
A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.遗传性血管神经性水肿中的一种生化异常：血清C1酯酶抑制剂缺失
Am J Med. 1963 Jul;35:37-44. doi: 10.1016/0002-9343(63)90162-1.
8
Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.缓激肽2型受体介导的C1抑制剂缺陷小鼠血管通透性增加。
J Clin Invest. 2002 Apr;109(8):1057-63. doi: 10.1172/JCI14211.
9
Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.热休克蛋白90在缺乏因子XII的情况下催化前激肽释放酶-激肽原复合物的激活。
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):896-900. doi: 10.1073/pnas.022626899. Epub 2002 Jan 15.
10
Activation of the kinin-forming cascade on the surface of endothelial cells.内皮细胞表面激肽形成级联反应的激活。
Biol Chem. 2001 Jan;382(1):71-5. doi: 10.1515/BC.2001.012.
Zotero 插件